Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. - Wikidata - awgldk - TriplyDB

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.

http://www.wikidata.org/entity/Q33423854

about

Therapeutic options in peripheral T cell lymphoma Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3.Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases.HDACs and HDAC Inhibitors in Cancer Development and Therapy.Targeting histone deacetylases in T-cell lymphoma.Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.The Current State of NAD(+) -Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets.Chidamide in the treatment of peripheral T-cell lymphoma The changing landscape of clinical trial and approval processes in China.Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.Combination of betulinic acid and chidamide synergistically inhibits Epstein-Barr virus replication through over-generation of reactive oxygen species.Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives.Design and Synthesis of Terephthalic Acid-Based Histone Deacetylase Inhibitors with Dual-Stage Anti-Plasmodium Activity.Combination of betulinic acid and chidamide inhibits acute myeloid leukemia by suppression of the HIF1α pathway and generation of reactive oxygen species.Recent advances in understanding and managing T-cell lymphoma.Chidamide shows synergistic cytotoxicity with cytarabine via inducing G0/G1 arrest and apoptosis in myelodysplastic syndromes.Mogamulizumab for the treatment of T-cell lymphoma.Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells.Exploring the effect of chidamide on blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review.Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma Histone deacetylase 6 in cancer

P2860

Q26748857-E4772025-B92B-463B-BE12-DBB8861EAA32 Q28070073-B7FFEF0D-2AD8-4C54-906F-46A0D57C6657 Q33435461-20C92725-2393-4D35-B5FD-7745DE04BE9A Q33436867-B981E717-AF8C-4AD5-94EC-32682A6DE560 Q37716435-CEBE5D39-49DD-40A4-8FD0-F5F8C0E7B0F9 Q38765451-1E9741E9-D498-4251-AC28-498EBC2C8196 Q38770098-FC7B4FF1-6509-44EA-8F89-7D7BBE5CE909 Q38826740-BEDB2B28-4DD7-4BAF-8C80-EC6B8C559E62 Q38947405-633D2339-AE07-458A-B51F-FBB70A184342 Q38998630-05BFE9AE-3CE9-436F-8A9E-363383E3A0EA Q39009379-3E944516-DFC7-4FBA-9206-9216722A9E82 Q39091771-058FBE32-B7DB-4F8B-8B85-F6BA41A6DB3C Q39110404-EB54A9D5-A02E-4019-85CA-DCA2A51219D0 Q39134733-8293723A-9469-4157-88EA-0F2AA5CB473C Q40103866-D64F47CB-6048-47E5-8F2D-B6C7E2535EE0 Q41392087-56FFA226-7CBC-4CCE-84F6-B56D6B8DF8B8 Q41924415-A57FD448-B66B-471B-931E-141C1346F451 Q42316356-FE6262EF-0AFF-457E-9DA1-8F48CF42C1BC Q45873027-FF363573-A71E-4767-B1A7-14D4BB2BCC3D Q46124569-C4F44B07-CEAC-47EF-ACBF-DB384DF540F2 Q46246664-89C2139F-F793-4E2F-8959-F20411824404 Q47131247-1730FEB9-EFFE-497C-BE4B-69607C4DEAB7 Q47220700-683EDF78-358E-434A-8044-91A28565B2E8 Q48223870-FAA1B69F-EC24-4FD6-9F58-29F69CCE7E26 Q48312107-90719FD0-0462-4EA2-9B81-7C058C0BDC37 Q48533275-E2B1BC48-1239-443F-AFC0-A173F01CBBE2 Q49409629-32A643B4-CAC6-442C-A335-858C88878F7F Q51738087-55956CD0-50F2-4E88-9D47-90BF12CE100A Q54964939-0FBC1945-3F1B-4D9B-874E-2432C892EF25 Q57298485-A337C706-3F25-486B-9BD1-0B374266FBC6 Q58701502-1CFE89F1-1BE0-446A-BD6B-4379FC901723 Q58768571-00FF0E80-07DC-4504-A20C-B13F42955273

P2860

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.

http://www.wikidata.org/entity/Q33423854

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Results from a multicenter, op ...... ry peripheral T-cell lymphoma.

@ast

Results from a multicenter, op ...... ry peripheral T-cell lymphoma.

@en

type

label

Results from a multicenter, op ...... ry peripheral T-cell lymphoma.

@ast

Results from a multicenter, op ...... ry peripheral T-cell lymphoma.

@en

prefLabel

Results from a multicenter, op ...... ry peripheral T-cell lymphoma.

@ast

Results from a multicenter, op ...... ry peripheral T-cell lymphoma.

@en

P1433

Q33423854-1778C5FF-8948-4A1D-A379-E3A3BC7ABBE9

P1476

Q33423854-60BF8BB7-BB19-4246-83F4-B527EEEF29BC

P2093

Q33423854-00A0E39B-B714-4E43-9CD1-1654B6CB1DBF

Q33423854-04D9FD19-9CF7-4011-B32F-51AD4ED8C9E9

Q33423854-2E5B955A-7349-464C-BE35-9EAEAB9F8955

Q33423854-39EA0284-E92B-4315-8180-9292B83F13B5

Q33423854-4FB49A56-7925-4CD3-AA49-C2C88ECF094B

Q33423854-6410203C-041E-41C3-8890-3D206F8C4715

Q33423854-65D8001D-7A86-4D7A-82EA-282235C025FB

Q33423854-868F57D7-4032-4287-8EE6-A680DA452FFC

Q33423854-ADF513AC-3542-4ECD-82EA-94004CA50D2E

Q33423854-AE07C837-5B30-4335-B9BA-C79FEE260BF9

P2860

Q33423854-011D995D-2ECE-4345-A310-B59C7B072128

Q33423854-06F9288F-9B3D-4944-95F9-EFEB9076BDF4

Q33423854-0AA91DC5-5606-4B6F-8B0B-69FED81AF864

Q33423854-40809C9D-B2B1-4562-8943-C7CF5D8E268D

Q33423854-5EA41578-F2ED-4158-9E64-B34E23BEA52A

Q33423854-6AF7808A-7816-4CCE-BC50-4F54874BCA93

Q33423854-6BF3A5D2-B031-4982-9A31-0EDC8A0356AB

Q33423854-706B3A50-30BF-46F0-A29F-A6F0AE02840B

Q33423854-8DF0DE87-B871-47C3-9991-C3881CBE48AE

Q33423854-9472ECB4-CD2F-4253-B423-D4CD04E97A42

P304

Q33423854-D391014A-FF5A-49FE-AEE9-7BEB6022795A

P31

Q33423854-93E0D4EF-63D8-4755-B1FD-A2AA4E8B194E

P356

Q33423854-BC433DCB-372B-432B-B42C-0AE64F51F20C

P433

Q33423854-69F25FF6-472A-4205-A32C-7A52227A92D9

P478

Q33423854-96726ADE-0762-486C-8D9E-9A0F82B14770

P577

Q33423854-359B5BF7-4C55-4649-83F9-D3AB9218BFC6

P698

Q33423854-55054B16-F473-48D0-85E8-F76CAD46859F

P921

Q33423854-EFDA7AE0-2A59-4651-AD9F-B91FF4CA1DB9

P356

P1433

Annals of Oncology

P1476

Results from a multicenter, op ...... ry peripheral T-cell lymphoma.

@en

P2093

D Zhou

http://www.w3.org/2001/XMLSchema#string

H Huang

http://www.w3.org/2001/XMLSchema#string

J Feng

http://www.w3.org/2001/XMLSchema#string

J Qi

http://www.w3.org/2001/XMLSchema#string

J Zhu

http://www.w3.org/2001/XMLSchema#string

L Yu

http://www.w3.org/2001/XMLSchema#string

M Dong

http://www.w3.org/2001/XMLSchema#string

W Li

http://www.w3.org/2001/XMLSchema#string

W Zhang

http://www.w3.org/2001/XMLSchema#string

X Hong

http://www.w3.org/2001/XMLSchema#string

P2860

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.

CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.

P304

1766-1771

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDV237

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26105599

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial